Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIST4721 in healthy male subjects using a standardized blister model
NCT04105959Phase 1Completed
- Sponsor
- Aristea Therapeutics
- Start
- Jul 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of vimnerixin in palmoplantar pustulosis (PPP) (2 cohorts), sponsored by Aristea Therapeutics. Primary endpoint: Absolute neutrophil count in blister fluid at 36 hours. Started Jul 2019; status: completed.
02
Drugs
vimnerixin
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04105959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105959.